comparemela.com

Latest Breaking News On - Apellis pharmaceuticals inc - Page 18 : comparemela.com

Global Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Industry Aims for US$ 1598 Million by 2033

The Global Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Industry, valued at US$ 638.96 Million in 2023, is set to experience unprecedented growth, reaching a staggering US$ 1598 Million by the year 2033. This impressive trajectory is driven by a robust Compound Annual Growth Rate (CAGR) of 9.6% between 2023 an.

Equities Research Analysts Updated EPS Estimates for February 6th (APLS, BGNE, BRBR, CRMT, CTLT, DASH, DSCV, FN, INCY, JNJ)

Equities Research Analysts’ updated eps estimates for Tuesday, February 6th: Apellis Pharmaceuticals (NASDAQ:APLS) had its outperform rating reissued by analysts at Robert W. Baird. They currently have a $81.00 target price on the stock. BeiGene (NASDAQ:BGNE) had its overweight rating reissued by analysts at JPMorgan Chase & Co.. They currently have a $185.00 price target […]

Apellis Pharmaceuticals (NASDAQ:APLS) Stock Rating Reaffirmed by Robert W Baird

Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report)‘s stock had its “outperform” rating reiterated by Robert W. Baird in a research note issued to investors on Tuesday, Benzinga reports. They currently have a $81.00 price target on the stock. Robert W. Baird’s target price points to a potential upside of 21.68% from the stock’s previous close. […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.